Abstract
duration were identified. Of these, 117 were identified as currently living in Berlin, and 86 of these agreed to participate in the study. Informed consent for collection of DNA samples for genetic studies and permission to review the medical records was obtained from all patients. A second group of patients (n=87), who had undergone first-time renal transplantation at our centre with a renal allograft survival of less than 3 years, served as primary controls. Besides demographic parameters (recipient and donor age, sex, BMI, presence of hypertension, antihypertensive drug therapy), we also compared the number of HLA-mismatches and cold ischaemia time between cases and controls. HLA mismatch points were calculated as one, three and five points for every A, B, or DR mismatch respectively. For the assessment of genotype and allelic frequencies, two further groups were genotyped: a sample of 170 healthy volunteers (age 33.8±9.9 years, 61% female) and 244 patients currently awaiting transplantation at our centre (age 46.5±12.1 years, 37% female).
Genotyping
Genomic DNA was prepared from peripheral white blood cells using routine DNA extraction techniques. Subsequently, the ACE I/D variant region was amplified with the polymerase chain reaction technique using a flanking primer pair as described previously [2] . In order to exclude mistyping of heterozygotes, all DD individuals were also examined using primers specific for the insertion variant as described previously [18] . Amplicons were visualized on 2.5% ethidiumbromide-stained agarose gels.
Statistical analysis
Allelic frequencies in the cases and controls were compared by x2 statistics. Clinical characteristics were compared by parametric or non-parametric tests for independent samples as appropriate. Data are presented as percentages, means±SD, or medians (range).
Results
Genotype distribution in long-term renal allograft survivors with an average graft survival of 156 (120-240) months (II, 18; ID, 41; DD, 27; qD, 0.55) was similar to that in the control group who had a mean allograft survival of 5.2 (0-35) months (II, 12; ID, 53; DD, 22; qD, 0.56). Allelic frequencies and genotype distribution in both groups were also not significantly different from those in the healthy volunteers (II, 38; ID, 68; DD, 64; qD, 0.58) or the patients on the waiting list (II, 65; ID, 120; DD, 59; qD, 0.49). There were no significant differences in BMI between cases and controls (Table 1) , but long-term survivors were more often female (58 vs 38%) and less often hypertensive (67 vs 77%). Both recipient and donor age were markedly lower in the long-term survivor group, whereas number of HLA mismatches and cold ischaemia time were comparable between cases and controls. There were no significant differences between the genotypic groups in either cases or controls. This clearly reflects the current shift in demographic Discussion characteristics of both the transplant recipients as well as the donor population in Germany. Despite these Our study was designed to test the hypothesis that differences between the long-term survivors and our there is a selective reduction in the frequency of the control group, it appears unlikely that these factors ACE-D allele in patients with long-term allograft surcan account for the similar frequencies of the ACE-D vival. Our observation that both the genotype distribuallele between patients with long-term and short-term tion and the frequency of the ACE-D-allele in patients allograft survival. with a mean renal allograft survival of more than 13 The lack of relationship between renal-allograft suryears was comparable to that of controls with early vival and the ACE I/D genotype does not completely graft loss clearly does not support this hypothesis.
rule out a role for increased ACE activity in the Also, the frequency of the ACE-D allele in the patients development of chronic allograft rejection or cardiowith long-term graft survival was practically identical vascular disease. Other hitherto unrecognized or to that reported previously in Caucasians by us [14, 17] unstudied variants of the ACE gene [24] might be and other investigators [2, 3] . Based on allele frequen-associated with either the development of end-stage cies, our study had a power of 0.8 to rule out an odds renal failure or the progression of renal injury includratio of 2.0 for reduced graft survival associated with ing chronic transplant rejection, and the ACE gene the ACE-D allele. Thus it appears unlikely that the therefore remains an attractive candidate gene. ACE-D allele will serve as a clinically useful predictor Furthermore, given that the development of chronic of poor long-term allograft survival in patients under-transplant rejection is probably the result of a complex going kidney transplantation.
interaction between a variety of immunological, genThe rationale for our study was based on the finding etic, and environmental factors [1], our study does not that the ACE-D allele may be a risk factor for both rule out an importance of the ACE genotype in certain the progression of chronic renal disease and for subsets of patients or under certain environmental increased mortality resulting from cardiovascular com-conditions. plications. Furthermore, the renin-angiotensin system
In conclusion, however, the present study does not has been implicated in the pathogenesis of chronic support the hypothesis that the ACE-I/D genotype is rejection [1], currently the leading cause of graft loss. an important determinant of long-term transplant surThe importance of the renin-angiotensin system for vival in Caucasians undergoing renal transplantation immune-mediated injury in renal [19] inhibition in hypertensives with renal transplants [22] .
Further rationale for the present study was provided by the recent observations that the ACE-D allele may References increase the risk of developing or influence the rate of progression of other forms of chronic kidney disease
